Assessment
lecanemab
Early Alzheimer's disease (mild cognitive impairment or mild dementia due to Alzheimer's disease) with confirmed amyloid pathology in ApoE ε4 non-carriers or heterozygous ApoE ε4 carriers
- Modules
- IQWiG assessments · G-BA decisions
- Connections
- 2
Connected evidence
2 relations